Celator announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Vyxeos (CPX-351) for the treatment of adults with therapy-related acute myelogenous leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). 

The designation is primarily based on positive results from the Phase 3 trial in older patients with previously untreated high-risk (secondary) AML. The study met its primary endpoint demonstrating a statistically significant improvement in overall survival for the Vyxeos arm compared to the 7+3 arm (median 9.56 months vs. 5.95 months, respectively). In addition, Vyxeos showed a 31% reduction in the risk of death vs. the 7+3 treatment (HR 0.69, P=0.005). The sixty-day all-cause mortality was 13.7% vs. 21.2%, in favor of patients treated with Vyxeos. Detailed study data will be presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in June. 

Related Articles

Celator intends to submit a New Drug Application (NDA) to the FDA by the end of the third quarter of 2016.

Vyxeos is an investigational, nano-scale, liposomal formulation of cytarabine and daunorubicin incorporated by the company’s proprietary CombiPlex platform.

For more information visit Celatorpharma.com.